0001415889-24-007715.txt : 20240312
0001415889-24-007715.hdr.sgml : 20240312
20240312190702
ACCESSION NUMBER: 0001415889-24-007715
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231003
FILED AS OF DATE: 20240312
DATE AS OF CHANGE: 20240312
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Seyedkazemi Setareh
CENTRAL INDEX KEY: 0001903088
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36579
FILM NUMBER: 24743986
MAIL ADDRESS:
STREET 1: C/O ADVERUM BIOTECHNOLOGIES, INC.
STREET 2: 100 CARDINAL DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adverum Biotechnologies, Inc.
CENTRAL INDEX KEY: 0001501756
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 205258327
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 CARDINAL WAY
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: (650) 649-1004
MAIL ADDRESS:
STREET 1: 100 CARDINAL WAY
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
FORMER COMPANY:
FORMER CONFORMED NAME: Avalanche Biotechnologies, Inc.
DATE OF NAME CHANGE: 20100921
4
1
form4-03122024_110354.xml
X0508
4
2023-10-03
0001501756
Adverum Biotechnologies, Inc.
ADVM
0001903088
Seyedkazemi Setareh
C/O ADVERUM BIOTECHNOLOGIES, INC.
100 CARDINAL WAY
REDWOOD CITY
CA
94063
false
true
false
false
CHIEF DEVELOPMENT OFFICER
0
Stock Option (Right to Buy)
1.29
2023-10-03
4
A
0
85000
0
A
2032-03-07
Common Stock
85000
85000
D
Reflects the meeting of the performance condition of performance stock options previously granted to the Reporting Person, pursuant to which 1/24 of the total number of shares subject to the option vest and become exercisable each month following the date upon which the first cohort of patients in the LUNA trial were fully dosed (the "Vesting Commencement Date"), such that all of the shares shall be vested and exercisable as of the second anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date. On October 3, 2023, the Issuer's Compensation Committee certified that the Vesting Commencement Date occurred on August 16, 2023.
/s/ John Rakow, Attorney-in-Fact
2024-03-12